CEO Buys 7% of Adia Labs Subsidiary for $350K Cash in Related-Party Deal
ADIA has more than doubled off its 52-week low of $0.025 on light trading volume (0.1× avg).
Summary
Adia Med's CEO bought a 7% membership interest in the Adia Labs subsidiary for $350,000 in cash, with use of proceeds controlled jointly by the two independent directors. It follows the October 5 sale of a 30% Adia Labs stake to Live Oak.
Key Events · M&A and Partnerships · ADIA
-
CEO Buys 7% of Adia Labs
Larry A. Powalisz purchased 7 membership units at $50,000 per unit, $350,000 total, paid entirely in cash, representing a 7% economic and voting interest in Adia Labs LLC.
-
Independent Directors Control Proceeds
The agreement bars the CEO from any unilateral decision on use of the $350,000; both independent directors, Monica Sher, M.D. and Richard Edwards, D.O., must approve in writing.
-
Follows October 5 Live Oak Stake Sale
Comes eight days after Adia Med sold a 30% Adia Labs stake to Live Oak Health LLC for $1.5 million; Live Oak consented to this transfer as an existing member.
-
Closing Conditions Pending
Units transfer only after full payment, an executed operating-agreement joinder, and an amendment reflecting the 7% voting power; the deal can be terminated if closing has not occurred within 10 days of the effective date.
Analysis · ADIA · Life Sciences
Why it matters: the CEO is putting $350,000 of his own cash into Adia Labs, the subsidiary where the company just sold a 30% stake to Live Oak on October 5. That is real money from a related party, and the structure is deliberately constrained: both independent directors must jointly approve in writing how the proceeds are used, and Powalisz has no unilateral authority over the cash. For a company carrying a going-concern warning, $350,000 is meaningful liquidity, and the governance guardrails are a notable counterweight to the conflict-of-interest optics of a CEO buying assets from his own company. The dilution here is at the subsidiary level, not the parent's share count.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADIA was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $0.03 to $0.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.